HEALTHCARE systems around the world are grappling with the arrival of a new kind of weight-loss treatment: injections based on the medicine semaglutide, which is branded as Wegovy or Ozempic.
The UK is among the first countries where semaglutide looks set to be made available for weight-loss treatment through a publicly funded health system. Unfortunately, many doctors think England’s guidance body has made a misstep by recommending people be restricted to two years of use, even though the drug is meant to be taken long-term. Health systems in other countries are also debating how to respond to this unprecedented situation,…